Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $1.07 Million - $1.24 Million
3,896 New
3,896 $1.11 Million
Q4 2022

Feb 10, 2023

BUY
$252.44 - $306.72 $24.5 Million - $29.8 Million
97,102 Added 270.01%
133,064 $36.8 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $6.53 Million - $9.01 Million
33,545 Added 1387.88%
35,962 $9.6 Million
Q2 2022

Aug 12, 2022

SELL
$187.54 - $223.02 $797,045 - $947,835
-4,250 Reduced 63.75%
2,417 $492,000
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $715,011 - $900,876
3,690 Added 123.95%
6,667 $1.4 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $566,741 - $728,345
-2,531 Reduced 45.95%
2,977 $714,000
Q3 2021

Nov 15, 2021

SELL
$282.99 - $369.05 $2.13 Million - $2.78 Million
-7,531 Reduced 57.76%
5,508 $1.56 Million
Q2 2021

Aug 16, 2021

BUY
$259.0 - $414.71 $3.38 Million - $5.41 Million
13,039 New
13,039 $4.52 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $6.88 Million - $8.06 Million
-28,316 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $6.69 Million - $10.1 Million
28,316 New
28,316 $6.93 Million
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $33.7 Million - $38.9 Million
-127,380 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$258.66 - $342.55 $32.9 Million - $43.6 Million
127,380 New
127,380 $34.1 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $351,924 - $446,421
-1,309 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $7.47 Million - $10.3 Million
-33,929 Reduced 96.29%
1,309 $388,000
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $2.21 Million - $2.47 Million
-10,148 Reduced 22.36%
35,238 $8.2 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $9.95 Million - $11 Million
45,386 New
45,386 $10.6 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.